Journal of the American Pharmacists Association : JAPhA · 2026
A quantitative and qualitative study of US FDA inspection reports of 503B outsourcing facilities.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
McCall Kenneth L, Lynch Sarah E, Hageman Elizabeth A, Williams Karl G
Аннотация
BACKGROUND: 503B outsourcing facilities were established under the Drug Quality and Security Act of 2013 to address safety concerns in pharmaceutical compounding by enabling large-scale sterile drug production under US Food and Drug Administration (FDA) oversight. Despite regulatory intent, concerns persist regarding inspection rates and compliance with current good manufacturing practices.
OBJECTIVE: This study aims to investigate FDA oversight, through analysis of inspection activity, of 503B outsourcing facilities registered during the period between 2020 and early 2025.
METHODS: This mixed-methods study analyzed FDA registration and inspection data from public databases for 48 503B outsourcing facilities registered from January 1, 2020 through April 30, 2025. Quantitative measures included inspection frequency, number of significant findings, and time to inspection. Qualitative thematic analysis was conducted on Form 483 and warning letters to identify recurring deficiencies.
RESULTS: Of 48 newly registered 503B facilities, only 11 (22.9%) had been inspected, with an average 2.2-year delay from registration to inspection. All inspected facilities had at least 2 significant objectionable findings (mean = 6.2, SD = 3.2). Thematic analysis of 68 findings revealed 5 major domains of deficiency: quality control, personnel training, documentation, process validation, and product labeling. Frequent issues included inadequate sterility testing, poor environmental controls, unvalidated production processes, and deficient recordkeeping.
CONCLUSIONS: The study reveals critical gaps in FDA oversight of 503B outsourcing facilities, characterized by delayed and infrequent inspections and widespread regulatory noncompliance. These deficiencies pose significant risks to patient safety, particularly in the production of sterile drugs. Immediate regulatory reforms, including adequate FDA funding to support increased inspection frequency, mandatory corrective actions, enhanced staff training, and greater transparency, are necessary to safeguard public health and ensure the integrity of compounded medications.
OBJECTIVE: This study aims to investigate FDA oversight, through analysis of inspection activity, of 503B outsourcing facilities registered during the period between 2020 and early 2025.
METHODS: This mixed-methods study analyzed FDA registration and inspection data from public databases for 48 503B outsourcing facilities registered from January 1, 2020 through April 30, 2025. Quantitative measures included inspection frequency, number of significant findings, and time to inspection. Qualitative thematic analysis was conducted on Form 483 and warning letters to identify recurring deficiencies.
RESULTS: Of 48 newly registered 503B facilities, only 11 (22.9%) had been inspected, with an average 2.2-year delay from registration to inspection. All inspected facilities had at least 2 significant objectionable findings (mean = 6.2, SD = 3.2). Thematic analysis of 68 findings revealed 5 major domains of deficiency: quality control, personnel training, documentation, process validation, and product labeling. Frequent issues included inadequate sterility testing, poor environmental controls, unvalidated production processes, and deficient recordkeeping.
CONCLUSIONS: The study reveals critical gaps in FDA oversight of 503B outsourcing facilities, characterized by delayed and infrequent inspections and widespread regulatory noncompliance. These deficiencies pose significant risks to patient safety, particularly in the production of sterile drugs. Immediate regulatory reforms, including adequate FDA funding to support increased inspection frequency, mandatory corrective actions, enhanced staff training, and greater transparency, are necessary to safeguard public health and ensure the integrity of compounded medications.